Small interfering RNA for cancer treatment: overcoming hurdles in delivery

Charbe, NB; Amnerkar, ND; Ramesh, B; Tambuwala, MM; Bakshi, HA; Aljabali, AAA; Khadse, SC; Satheeshkumar, R; Satija, S; Metha, M; Chellappan, DK; Shrivastava, G; Gupta, G; Negi, P; Dua, K; Zacconi, FC

Small interfering RNA for cancer treatment: overcoming hurdles in delivery

Charbe, NB Amnerkar, ND Ramesh, B Tambuwala, MM Bakshi, HA Aljabali, AAA Khadse, SC Satheeshkumar, R Satija, S

Metha, M Chellappan, DK Shrivastava, G Gupta, G Negi, P Dua, K

Zacconi, FC

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Acta Pharmaceutica Sinica B, 2020, 10, (11), pp. 2075-2109
Issue Date:: 2020-01-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.55 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Charbe, NB
dc.contributor.author	Amnerkar, ND
dc.contributor.author	Ramesh, B
dc.contributor.author	Tambuwala, MM
dc.contributor.author	Bakshi, HA
dc.contributor.author	Aljabali, AAA
dc.contributor.author	Khadse, SC
dc.contributor.author	Satheeshkumar, R
dc.contributor.author	Satija, S https://orcid.org/0000-0003-4702-6534
dc.contributor.author	Metha, M
dc.contributor.author	Chellappan, DK
dc.contributor.author	Shrivastava, G
dc.contributor.author	Gupta, G
dc.contributor.author	Negi, P
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Zacconi, FC
dc.date.accessioned	2020-12-10T03:39:12Z
dc.date.available	2020-12-10T03:39:12Z
dc.date.issued	2020-01-01
dc.identifier.citation	Acta Pharmaceutica Sinica B, 2020, 10, (11), pp. 2075-2109
dc.identifier.issn	2211-3835
dc.identifier.issn	2211-3843
dc.identifier.uri	http://hdl.handle.net/10453/144620
dc.description.abstract	© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies.
dc.language	en
dc.publisher	Elsevier BV
dc.relation.ispartof	Acta Pharmaceutica Sinica B
dc.relation.isbasedon	10.1016/j.apsb.2020.10.005
dc.rights	Elsevier required licence: © 2020 . This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/. The definitive publisher version is available online at https://doi.org/10.1016/j.apsb.2020.10.005	en_US
dc.rights	info:eu-repo/semantics/openAccess
dc.rights	Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hostingby Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.title	Small interfering RNA for cancer treatment: overcoming hurdles in delivery
dc.type	Journal Article
utslib.citation.volume	10
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
dc.date.updated	2020-12-10T03:39:08Z
pubs.issue	11
pubs.publication-status	Published
pubs.volume	10
utslib.citation.issue	11

Abstract:

© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/144620